The FDA initially expressed concern about the high cancer rates among clinical study patients receiving Amplify for posterlateral lumbar fusion, but the FDA’s Orthopaedic and Rehabilitation Devices panel voted 6-5, just narrowly recommending to the FDA that the device be approved in July 2010.
In a filing with the Securities and Exchange Commission, Medtronic said the FDA would not approve Amplify without additional information from the company but did not make mention of what data segments were requested, according to the news report.
Following the FDA’s decision, Medtronic shares plummeted 2.8 percent.
Read the news report about FDA’s rejection of Medtronic’s Amplify.
Read other coverage about Medtronic’s Amplify:
– FDA Panel Votes to Recommend Approval for Medtronic’s Amplify Spine Device
– Millennium Research Group: Bone Graft Substitute Market to Reach $2.3B by 2015
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
